|
|
|
|
|
Rocha,Paulo Ricardo Dell'Armelina; Lopes,Letícya Lerner; Arruda,Laura Peixoto de; Pescador,Caroline Argenta; Cruz,Raquel Aparecida Sales da; Colodel,Edson Moleta. |
Cholangiocarcinomas are neoplasms that originate from the bile duct epithelium. The present case described a cholangiocarcinoma in an adult female American Rhea (Rhea Americana araneipes) by means of gross, histopathology and immunohistochemistry. Irregular, firm, multifocal, yellow-white masses, measuring from 0.4 to 6cm in diameter were observed in both liver lobes. At the cut surface, multiple firm nodules filled with connective tissue were present. Microscopically, the neoplasia was composed of small, irregular, gland-like structures of neoplastic cells surrounded by connective tissue. The cells resembled epithelial cells of the hepatic biliary ducts. Neoplastic cells were positive for cytokeratin and negative for vimentin. This is the first report of... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Cholangiocarcinoma; Rhea; Immunohistochemistry; Wildlife. |
Ano: 2015 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782015000200284 |
| |
|
|
Yu,Z.; Cheng,H.; Zhu,H.; Cao,M.; Lu,C.; Bao,S.; Pan,Y.; Li,Y.. |
Chemotherapy response rates in patients with cholangiocarcinoma remain low, primarily due to the development of drug resistance. Epithelial-mesenchymal transition (EMT) of cancer cells is widely accepted to be important for metastasis and progression, but it has also been linked to the development of chemoresistance. Salinomycin (an antibiotic) has shown some potential as a chemotherapeutic agent as it selectively kills cancer stem cells, and has been hypothesized to block the EMT process. In this study, we investigated whether salinomycin could reverse the chemoresistance of cholangiocarcinoma cells to the chemotherapy drug doxorubicin. We found that combined salinomycin with doxorubicin treatment resulted in a significant decrease in cell viability... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Chemotherapy; Cholangiocarcinoma; Drug resistance; Doxorubicin; Salinomycin. |
Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001000607 |
| |
|
|
|